



February 22, 2016

**Allysta Pharmaceuticals, Inc. to present at the QB3 – 2017 Life Science Pitch Summit**

Allysta Pharmaceuticals, Inc. (Allysta) today announced that Henry Hsu, M.D., the company's chief executive officer, will present at the QB3 – 2017 Life Science Pitch Summit on March 2, 2017, in San Francisco.

**About QB3**

QB3's domain is the "quantitative biosciences," in which scientists take on challenges in biology using the techniques of physics, chemistry and computer science. QB3's faculty members' - professors at UC Berkeley, UC Santa Cruz, and UCSF - comprehensive approach enables UC to convert life science research into solutions for better health, a sustainable environment and a dynamic economy

**About Allysta**

Allysta is a private company developing breakthrough therapies with a focus in eye diseases. The company is advancing next-generation treatments for two major areas in ophthalmology: dry eye disease and glaucoma. Allysta's lead candidates are in late preclinical stage supported by compelling science and pharmacology.